Luyan Pharma Co.,Ltd.
SZSE:002788.SZ
8.78 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 19,845.535 | 19,462.501 | 17,545.397 | 15,531.278 | 15,008.876 | 11,500.891 | 8,338.233 | 6,982.885 | 6,625.72 | 6,299.802 | 5,519.752 | 4,687.352 | 2,948.581 |
| Cost of Revenue
| 18,336.47 | 17,947.345 | 16,174.212 | 14,297.099 | 13,839.484 | 10,600.987 | 7,688.429 | 6,452.68 | 6,097.548 | 5,763.359 | 5,048.625 | 4,327.219 | 2,714.515 |
| Gross Profit
| 1,509.064 | 1,515.157 | 1,371.185 | 1,234.179 | 1,169.392 | 899.904 | 649.804 | 530.205 | 528.172 | 536.443 | 471.127 | 360.134 | 234.067 |
| Gross Profit Ratio
| 0.076 | 0.078 | 0.078 | 0.079 | 0.078 | 0.078 | 0.078 | 0.076 | 0.08 | 0.085 | 0.085 | 0.077 | 0.079 |
| Reseach & Development Expenses
| 5.534 | 4.146 | 2.972 | 3.861 | 5.188 | 2.643 | 0.628 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 47.672 | 47.328 | 43.122 | 36.045 | 42.336 | 39.64 | 29.478 | 25.535 | 22.093 | 25.303 | 26.352 | 18.288 | 59.678 |
| Selling & Marketing Expenses
| 441.713 | 432.773 | 379.335 | 344.262 | 322.602 | 217.18 | 168.22 | 141.303 | 136.135 | 155.623 | 129.733 | 100.981 | 64.446 |
| SG&A
| 489.385 | 480.102 | 422.458 | 380.307 | 364.938 | 256.819 | 197.698 | 166.838 | 158.228 | 180.926 | 156.085 | 119.269 | 124.124 |
| Other Expenses
| 0.865 | 285.691 | 307.513 | 262.533 | 266.326 | -1.173 | 1.848 | 3.434 | 3.505 | 5.736 | 1.761 | 1.941 | 0.642 |
| Operating Expenses
| 788.425 | 769.939 | 732.943 | 646.7 | 636.452 | 505.518 | 368.075 | 299.86 | 283.36 | 302.392 | 257.321 | 192.95 | 128.775 |
| Operating Income
| 468.556 | 740.434 | 645.087 | 589.096 | 547.014 | 260.938 | 198.647 | 154.021 | 152.227 | 146.181 | 145.522 | 121.313 | 85.521 |
| Operating Income Ratio
| 0.024 | 0.038 | 0.037 | 0.038 | 0.036 | 0.023 | 0.024 | 0.022 | 0.023 | 0.023 | 0.026 | 0.026 | 0.029 |
| Total Other Income Expenses Net
| 0.865 | -274.424 | -229.872 | -216.976 | -202.938 | -134.621 | -81.234 | -72.92 | -89.103 | -82.165 | -66.531 | -43.943 | -19.384 |
| Income Before Tax
| 469.422 | 466.01 | 415.215 | 372.12 | 344.076 | 259.765 | 200.495 | 157.426 | 155.709 | 151.885 | 147.274 | 123.241 | 85.907 |
| Income Before Tax Ratio
| 0.024 | 0.024 | 0.024 | 0.024 | 0.023 | 0.023 | 0.024 | 0.023 | 0.024 | 0.024 | 0.027 | 0.026 | 0.029 |
| Income Tax Expense
| 104.927 | 115.036 | 110.604 | 104.311 | 86.566 | 75.184 | 55.489 | 40.653 | 40.503 | 40.913 | 38.158 | 31.864 | 22.029 |
| Net Income
| 363.53 | 345.155 | 305.871 | 266.628 | 255.889 | 180.325 | 130.579 | 115.523 | 113.48 | 109.327 | 108.283 | 90.514 | 63.625 |
| Net Income Ratio
| 0.018 | 0.018 | 0.017 | 0.017 | 0.017 | 0.016 | 0.016 | 0.017 | 0.017 | 0.017 | 0.02 | 0.019 | 0.022 |
| EPS
| 0.94 | 0.89 | 0.79 | 0.69 | 0.73 | 0.51 | 0.37 | 0.35 | 0.43 | 0.42 | 0.41 | 0.34 | 0.24 |
| EPS Diluted
| 0.94 | 0.89 | 0.79 | 0.69 | 0.73 | 0.51 | 0.37 | 0.35 | 0.43 | 0.42 | 0.41 | 0.34 | 0.24 |
| EBITDA
| 839.454 | 853.212 | 757.859 | 636.681 | 589.123 | 434.45 | 313.659 | 248.381 | 257.749 | 248.951 | 223.576 | 171.806 | 109.437 |
| EBITDA Ratio
| 0.042 | 0.044 | 0.043 | 0.041 | 0.039 | 0.038 | 0.038 | 0.036 | 0.039 | 0.04 | 0.041 | 0.037 | 0.037 |